Investigación: AOD-9604

Modified growth hormone fragment for fat burning

AOD-9604 Research Papers & Clinical Studies

AOD-9604 is a peptide studied for its potential therapeutic effects. Modified growth hormone fragment for fat burning This page indexes all published research papers, clinical trials, and scientific studies related to AOD-9604 that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific AOD-9604 applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 3 research papers indexed for AOD-9604.

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main AOD-9604 profile page.

AOD-9604

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Endocrinology 2001 500 Animal Study

AOD9604 (GH lipolytic fragment) reduced body weight and body fat in obese mice after 14 days, increasing beta(3)-adrenergic receptor expression in fat cells.

AOD-9604 Metabolic

Curr Opin Investig Drugs 2004 440 Research Article

Metabolic Pharmaceuticals developed AOD-9604 for obesity treatment, with Phase IIa trials underway as of 2002 for this lipolytic peptide fragment of human GH.

Obesity drugs in clinical development

Curr Opin Investig Drugs 2006 400 Research Article

Review of anti-obesity drugs in clinical development including centrally-acting agents, peripheral satiety signal targets like GLP-1, and other weight loss mechanisms.